NASDAQ$BTAI
Bioxcel Therapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported first quarter results, with a net loss of $14.9 million, and provided a business update, highlighting progress in clinical trials for BXCL501 and BXCL701.
BioXcel Therapeutics reported a net loss of $14.9 million for the first quarter of 2020. The company highlighted progress in its clinical trials for BXCL501 and BXCL701 and strengthened its balance sheet through a follow-on offering, raising approximately $60 million in net proceeds.
- Advanced BXCL501 clinical trials (SERENITY I & II and TRANQUILITY) and initiated Phase 1b/2 RELEASE trial.
- Investigating biomarkers associated with agitation to expand the potential market for BXCL501.
- Identified the recommended dose of BXCL701 for Phase 2 efficacy trial in combination with KEYTRUDA® for treatment emergent Neuroendocrine Prostate Cancer.
- Strengthened balance sheet through follow-on offering raising approximately $60 million in net proceeds.
Headline financials
Revenue & EPS history
Bioxcel Therapeutics · Revenue · Quarterly
$0
Revenue by segment
Bioxcel Therapeutics · $206K total across 1 segment · Q1 2026
- IGALMI$206K—100.0%
Forward guidance
BioXcel Therapeutics is progressing with clinical trials for BXCL501 and BXCL701, with topline data expected in mid-2020 for the SERENITY trials and results for the TRANQUILITY study also expected in mid-2020. The company is monitoring the impact of the COVID-19 pandemic on its clinical and corporate plans.
Tailwinds
- Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020.
- The Company is assessing data for dose escalation in the TRANQUILITY study and is on track to report results in mid-2020.
- Recommended Phase 2 dose of BXCL701 identified for combination study with KEYTRUDA®, leading to the initiation of the Phase 2 efficacy trial for advanced prostate cancer.
- Strengthened balance sheet through follow-on offering raising approximately $60 million in net proceeds.
- To date, the Company has not experienced any significant delays with its ongoing clinical trials and have developed a risk mitigation strategy to manage business operations.
Headwinds
- Reported a net loss of $14.9 million for the first quarter of 2020, compared to a net loss of $7.2 million for the same period in 2019.
- The first quarter 2020 results include approximately $0.8 million in non-cash stock-based compensation.
- Research and development expenses were $12.4 million for the first quarter of 2020, as compared to $5.7 million for the same period in 2019.
- General and administrative expenses were $2.6 million for the first quarter of 2020, as compared to $1.7 million for the same period in 2019.
- To date, the Company has not experienced any significant delays to its ongoing or planned clinical trials; however, this could rapidly change.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
-3.1%
Avg return
Earnings day
-5.6%
Avg return
5 days after
-10.0%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+38.7%
Q3 2022
Best reaction
-44.1%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.8% | -9.9% | — | |
| Q4 2025 | -5.6% | -10.9% | -22.6% | |
| Q3 2025 | -16.0% | -9.4% | -0.5% | |
| Q2 2025 | +6.5% | -14.4% | -47.0% | |
| Q1 2025 | +0.0% | -4.8% | +6.8% | |
| Q4 2024 | +6.0% | -11.9% | -14.2% | |
| Q3 2024 | -8.2% | -2.6% | -33.4% | |
| Q2 2024 | -1.0% | -20.5% | -35.9% | |
| Q1 2024 | -1.4% | +0.5% | -33.3% | |
| Q4 2023 | -1.0% | -7.6% | -3.8% | |
| Q3 2023 | -20.1% | -25.0% | -41.2% | |
| Q2 2023 | -44.1% | -41.5% | -54.3% | |
| Q1 2023 | +17.7% | +18.6% | -9.6% | |
| Q4 2022 | -27.2% | -28.3% | -39.1% | |
| Q3 2022 | +38.7% | +41.1% | +49.2% | |
| Q2 2022 | -9.7% | -5.9% | -9.4% | |
| Q1 2022 | -10.6% | -6.5% | -6.7% | |
| Q4 2021 | -8.3% | -20.3% | -9.4% | |
| Q3 2021 | -2.4% | -19.7% | -35.5% | |
| Q2 2021 | +2.2% | -1.6% | +19.3% | |
| Q1 2021 | +8.1% | +3.1% | +27.2% | |
| Q4 2020 | +3.8% | +2.0% | -20.7% | |
| Q3 2020 | -4.1% | -8.6% | -23.8% | |
| Q2 2020 | -4.7% | -6.3% | +0.5% | |
| Q1 2020 | +0.1% | +9.6% | +6.7% | |
| Q4 2019 | -3.9% | -39.8% | -35.5% | |
| Q3 2019 | +12.4% | +40.6% | +48.3% | |
| Q2 2019 | -15.1% | -7.5% | +2.6% | |
| Q1 2019 | +12.8% | +9.4% | +5.3% | |
| Q4 2018 | -6.6% | +12.3% | +23.1% | |
| Q3 2018 | -7.9% | -12.6% | -21.8% | |
| Q2 2018 | -1.8% | -9.6% | -8.5% | |
| Q1 2018 | -4.9% | +3.6% | -1.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro